News Sentiment

MIST sentiment intelligence

Milestone Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.28 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-3.0% over one week, +0.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -3.0% Price reacting lower
Trend fit Trend inactive 0.8% over four weeks
Fair value -31.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 45
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
TradingView 9
Market source 9
simplywall.st 5
TradingKey 3
Seeking Alpha 2
GlobeNewswire 2
Zacks Investment Research 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 21
Analyst action 4
Deals and strategy 2
Regulatory and legal 2
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Insider Monkey Direct company coverage

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported its Q1 2026 earnings, detailing the early commercial launch of CARDAMYST for acute PSVT episodes and the initiation of its Phase III trial for etripamil in AFib-RVR. The company notes positive initial responses from healthcare

Tone
Positive 65/100
Event
Earnings
Published
14 May 2026 12:39
Source
Insider Monkey
Stock Titan Direct company coverage

NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19

Milestone Pharmaceuticals (NASDAQ: MIST) announced it will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, featuring a 3:00 p.m. ET fireside chat available via webcast. The company, focused on innovative cardiovascular medicines

Tone
Negative 39/100
Event
Market update
Published
14 May 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

Milestone (Nasdaq: MIST) posts Q1 loss as first CARDAMYST sales begin

Milestone Pharmaceuticals (Nasdaq: MIST) reported a widened net loss in Q1 2026, reaching $26.1 million, despite initiating its first product sales of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT), generating $0.2 million in revenue. The company increased commercia

Tone
Negative 40/100
Event
Earnings
Published
14 May 2026 09:10
Source
Stock Titan
MarketBeat Direct company coverage

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals reported the start of commercial sales for its PSVT treatment, CARDEMYST, in Q1 2026, with approximately 600 prescriptions written by the end of April and steady month-over-month growth. The company also announced improved payer coverage with CARDEMYST a

Tone
Positive 82/100
Event
Earnings
Published
14 May 2026 08:09
Source
MarketBeat
Moomoo Direct company coverage

Milestone Pharmaceuticals Files $300 Million Mixed Shelf

Milestone Pharmaceuticals has filed a mixed shelf registration statement with the SEC, allowing it to offer and sell up to $300 million in various securities. This filing provides the company with financial flexibility for future capital-raising activities. The specific terms of

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 23:38
Source
Moomoo
TradingView Direct company coverage

Milestone Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $6.33, Implies 233% Upside

Milestone Pharmaceuticals Inc.'s average 12-month price target has been reduced from $6.5 to $6.33 by six analysts, implying a 233% potential upside from its May 12 closing price. The consensus rating for MIST remains a "Buy," with five analysts recommending Buy and one recommend

Tone
Positive 71/100
Event
Analyst action
Published
13 May 2026 22:38
Source
TradingView